天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Toggle Nav
Close
  • Menu
  • Setting

NSC 687852 (b-AP15)

Catalog No.
A4453
19S regulatory particle Inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$88.00
In stock
10mg
$83.00
In stock
50mg
$267.00
In stock
200mg
$575.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

IC50: N/A

NSC 687852 is a 19S regulatory particle inhibitor.

The 19S particles bind polyubiquitin-linked polypeptides and present them to the 20S degradative units. USP14 and UCHL5 are cysteine enzymes that become activated after being associated with the proteasome.

In vitro: NSC 687852 blocked deubiquitylating activity of USP14 and UCHL5 selectively without inhibiting proteasome activity. NSC 687852 decreased viability in multiple myeloma (MM) cell lines and patient MM cells, inhibited MM cell proliferation even in the presence of bone marrow stroma cells, and overcomed bortezomib resistance. Anti-MM activity of NSC 687852 was associated with growth arrest through downregulating CDC2, CDC25C, and cyclin B1, as well as induction of caspase-dependent apoptosis and activation of unfolded protein response [1].

In vivo: In vivo studies using distinct human MM xenograft models showed that NSC 687852 was well tolerated, inhibited tumor growth, and prolonged mouse survival. Combination of NSC 687852 with suberoylanilide hydroxamic acid, lenalidomide, or dexamethasone was found to induce synergistic anti-MM activity [1].

Clinical trial: N/A

Reference:
[1] Ze Tian,Padraig D'Arcy,Xin Wang,Arghya Ray,Yu-Tzu Tai,Yiguo Hu,Ruben D Carrasco,Paul Richardson,Stig Linder,Dharminder Chauhan,Kenneth C Anderson.  A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30; 123(5): 706–716.

Chemical Properties

StorageStore at 4°C
M.Wt419.39
Cas No.1009817-63-3
FormulaC22H17N3O6
Synonymsb-AP15
Solubilityinsoluble in EtOH; insoluble in H2O; ≥20.95 mg/mL in DMSO
Chemical Name(3E,5E)-3,5-bis[(4-nitrophenyl)methylidene]-1-prop-2-enoylpiperidin-4-one
SDFDownload SDF
Canonical SMILESC=CC(=O)N1CC(=CC2=CC=C(C=C2)[N+](=O)[O-])C(=O)C(=CC3=CC=C(C=C3)[N+](=O)[O-])C1
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:

Cell lines

Bacterial lipopolysaccharide (LPS)-primed macrophages prepared from adult male C57BL/6 mice(Harlan)LPS-primed THP-1 cells(to induce pro-IL-1β expression before nigericin treatment)

Preparation method

The solubility of this compound in DMSO is >21mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

1μM

Applications

Pretreatment with NSC 687852 inhibited ATP-induced IL-1β release from LPS-primed peritoneal macrophages and nigericin-induced release from LPS-primed THP-1 cells and reduced the levels of cell death induced by nigericin treatment in THP-1 cells. In macrophages, NSC 687852 also caused an increase in polyubiquitinated proteasomal substrates. In LPS-primed THP-1 cells, NSC 687852 significantly reduced the numbers of ASC specks formed after nigericin treatment. Similarly, ATP-induced speck formation in murine peritoneal macrophages was also inhibited by NSC 687852.
Animal experiment [2]:

Animal models

combined immunodeficiency (SCID) mice with FaDu squamous carcinoma xenografts;mice with HCT-116 colon carcinoma xenografts overexpressing BCL2

Dosage form

daily subcutaneous injection ;5 mg per kg of body weight

Application

When administered NSC 687852 daily to severe combined immunodeficiency (SCID) mice with FaDu squamous carcinoma xenografts, there was a significant antitumor activity. When analyzed tumor death by measuring xenograft-derived CK18 in circulation, there was a significant increase in the plasma concentrations of total CK18 as well as increased concentrations of caspase-cleaved CK18 (CK18-Asp396) , showing that NSC 687852 had activity against tumor cells in vivo. When also examined disease-free survival in mice with HCT-116 colon carcinoma xenografts overexpressing BCL2, NSC 687852 treatment significantly delayed tumor onset compared to vehicle-treated controls, with two out of six of the mice treated with NSC 687852 being completely disease free at the end of the study.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Lopez-Castejon G,Luheshi NM,Compan V., et al. Deubiquitinases regulate the activity of caspase-1 and interleukin-1β secretion via assembly of the inflammasome. J Biol Chem.2013 Jan 25;288(4):2721-33. doi: 10.1074/jbc.M112.422238. Epub 2012 Dec 3.

[2]. D'Arcy P,Brnjic S,Olofsson MH., et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med.2011 Nov 6;17(12):1636-40. doi: 10.1038/nm.2536.

Quality Control